Medicine
Migergot 100 mg/2 mg suppository
Migergot 100 mg/2 mg suppository is a prescription medicine containing Caffeine and Ergotamine for rectal use, marketed by Cosette Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store and Dispense The suppositories should be refrigerated at 2° to 8°C (36°…
Key facts
- Active ingredient (INN)
- Caffeine and Ergotamine
- Brand
- Migergot
- Strength
- 100 mg/2 mg
- Dosage form
- Suppository
- Route
- Rectal
- Packs
- 12 suppositories
- Marketing authorisation holder
- Cosette Pharmaceuticals
- Manufacturer
- Cosette Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store and Dispense The suppositories should be refrigerated at 2° to 8°C (36° to 46°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 October 1983
- Identifiers
- RxCUI 1293508, 1293639DailyMed set ID 3a31ad0c-7bdd-544b-f5df-a99d04cf541cNDC 0713-0166Application ANDA086557
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 12 suppository in 1 box | 0713-0166-12 | Cosette Pharmaceuticals | 30 October 1983 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 November 1948 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Caffeine and Ergotamine
Clinical summary
Caffeine and Ergotamine is a fixed-dose combination of a central nervous system stimulant, an ergotamine derivative and a methylxanthine indicated as therapy to abort or prevent vascular headache, e.g., migraine, among other approved uses. MedsAcross supplies Caffeine and Ergotamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Caffeine and ErgotamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cafergot prescribing information (Trifluent Pharma) · U.S. National Library of Medicine, DailyMed
Need Migergot 100 mg/2 mg suppository for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.